EU Clinical Trial 2019-001095-11

RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR-1 (rhIGF-1) TREATMENT OF SHORT STATURE ASSOCIATED WITH PRIMARY IGF-1 DEFICIENCY: A MULTICENTER, OPEN-LABEL, CONCENTRATION-CONTROLLED TRIAL  May 31, 2019

Main objective of the trial: The objective of this study is to assess the effects of once daily dosing with rhIGF-1 in increasing height velocity in prepubertal subjects with growth failure associated with Primary IGF Deficiency.

Parties

Sponsors
Countries
EU US
Keywords
Increlex Mecasermin

JSON preview

Similar records

Title

Source:  EMA Last updated:  Jun 5, 2019

From ClinicalTrialsRegister.eu, a database of the European Medicines Agency. This record may not reflect the most current and accurate data available from the EMA.